Latest news with #Natera
Yahoo
4 days ago
- Business
- Yahoo
3 Mid-Cap Stocks Worth Your Attention
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments. Digging up these buried treasures isn't easy, and that's exactly why we created StockStory. That said, here are three of our favorite mid-cap stocks that could amplify your portfolio's returns. Market Cap: $15.99 billion Playing on the secular trend of healthier living, Sprouts Farmers Market (NASDAQ:SFM) is a grocery store chain emphasizing natural and organic products. Why Do We Watch SFM? Aggressive strategy of rolling out new stores to gobble up whitespace is prudent given its same-store sales growth Comparable store sales rose by 6.6% on average over the past two years, demonstrating its ability to drive increased spending at existing locations Free cash flow margin grew by 2.1 percentage points over the last year, giving the company more chips to play with Sprouts is trading at $163 per share, or 33.6x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it's free. Market Cap: $20.94 billion Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ:NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology. Why Is NTRA a Good Business? Products are reaching more customers as its tests processed averaged 23.1% growth over the past two years Adjusted operating profits and efficiency rose over the last two years as it benefited from some fixed cost leverage Free cash flow profile has moved into positive territory over the last five years, showing the company has crossed a key inflection point Natera's stock price of $153.89 implies a valuation ratio of 10.1x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it's free. Market Cap: $13.39 billion With roots dating back to 1914 and deep ties to nearly all U.S. cabinet-level departments, Booz Allen Hamilton (NYSE:BAH) provides management consulting, technology services, and cybersecurity solutions primarily to U.S. government agencies and military branches. Why Are We Backing BAH? Market share has increased this cycle as its 13.7% annual revenue growth over the last two years was exceptional Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 12.9% over the past two years Share repurchases have amplified shareholder returns as its annual earnings per share growth of 14.9% exceeded its revenue gains over the last five years At $108.40 per share, Booz Allen Hamilton trades at 15.7x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
Yahoo
22-05-2025
- Business
- Yahoo
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Studies include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera Breast: 8 accepted abstracts (4 oral presentations), including interim analysis from the randomized Signatera-guided interventional DARE trial; a large real-world study of metastatic treatment monitoring; and two readouts from the ISPY-2 trial Signatera Genome: Large-scale, pan-cancer performance of Signatera Genome assay GI, GU, Skin, Sarcoma: Significance of Signatera MRD and dynamics to predict recurrence, progression, and treatment response across multiple disease subtypes AUSTIN, Texas, May 22, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera's leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment. "The depth and breadth of Natera's research at ASCO is our most significant to date, with multiple impactful datasets in several histologies," said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. "The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed." Highlights include: DARE Clinical Trial: Oral Presentation DARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of "treatment on molecular recurrence" (TOMR). Patients who were Signatera-positive and imaging-negative were randomized into two arms: the standard-of-care (SOC) arm with endocrine therapy vs. the escalated arm with fulvestrant+palbociclib (CDK 4/6i). This interim analysis of 507 women and 2,208 plasma samples demonstrates the exceptional clinical performance of Signatera, and the early feasibility of both this treatment escalation approach and the TOMR trial strategy, including: Strong test sensitivity and NPV: Among patients who remained persistently Signatera-negative during screening (>400 pts), 99% remained recurrence free with a median follow up of 27.4 months. High randomization rate: Of patients who tested Signatera-positive, 73% were negative on imaging, and 93% were willing to be randomized. 2x higher ctDNA clearance: Patients in Arm A had a 2x higher rate of ctDNA clearance at 3 months vs. Arm B. Signatera Monitoring in Metastatic Breast Cancer: Oral Presentation This real-world analysis of over 600 metastatic breast cancer (mBC) patients across all disease subtypes and a wide range of therapeutic regimens (e.g., chemo, ADCs, CDK4/6) shows the utility of metastatic monitoring with Signatera: Serial ctDNA testing done at an appropriate cadence (6 weeks) can inform treatment response and clinical decisions in metastatic breast cancer. Signatera ctDNA dynamics were the strongest predictor of treatment benefit in a multivariate analysis, based on measuring time to next treatment (TTNT). Nearly 75% of patients with favorable dynamics remained on the same treatment for over 4 months, including those receiving antibody drug conjugates (ADCs) where therapy response can be challenging to evaluate on imaging. Pan-Cancer Performance of Signatera Genome: Poster Presentation Large-scale presentation of Signatera's Genome assay, analyzing more than 3,000 samples from over 300 patients across 5 major cancer types. The study includes analysis of patients with breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma. Signatera Performance in Post-Surgical Stage I-IIIb Melanoma: Poster Presentation This study includes 197 patients and 1,681 plasma samples, tested for a median period of 2 years. This is one of the most comprehensive MRD/monitoring datasets thus far in early melanoma, demonstrating the ability of Signatera to identify patients who may benefit from escalated imaging or earlier treatment initiation. Post-surgical Signatera-positivity was the most significant predictor of recurrence free survival (RFS). In the surveillance setting, Signatera-positivity was predictive of shorter RFS (HR: 24.0, P < 0.001). Full list of oral presentations at ASCO: May 30, 2:45 PM CT | 3008 | BreastPresenter: Silver AlkhafajiCirculating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial June 1, 9:45 AM CT | 4503 | GenitourinaryPresenter: Thomas Powles, MBBS, MRCP, tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA June 1, 11:30 AM CT | 3518 | GastrointestinalPresenter: Aron Bercz, Tumor DNA Provides an Early Response Assessment in Anal Squamous Cell Carcinoma Treated With Definitive Chemoradiation June 1, 4:30 PM CT | 1010 | BreastPresenter: Lajos Pusztai, M.D., DPhilCirculating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer (BC) during adjuvant endocrine therapy (ET) (DARE) June 1, 4:30 PM CT | 1011 | BreastPresenter: Pedram Razavi, M.D., tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC) June 2, 3:00 PM CT | 504 | BreastPresenter: Rita Mukhtar, nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial Full list of poster presentations at ASCO: May 31, 9:00 AM CT | 11537 | SarcomaPresenter: Adie Victor, M.D., on-treatment circulating tumor (ct)DNA dynamics in response to therapy in patients with sarcoma May 31, 9:00 AM CT | 11531 | SarcomaPresenter: Maggie Zhou, assessment of response to chemotherapy via ctDNA in soft tissue sarcoma May 31, 9:00 AM CT | TPS3647 | GastrointestinalPresenter: Clara Montagut, M.D.A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS Trial. May 31, 9:00 AM CT | 4067 | Gastrointestinal - FMIPresenter: Michele Prisciandaro, liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: the LIQUID study May 31, 9:00 AM CT | 4130 | GastrointestinalPresenter: Maen Abdelrahim, analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer May 31, 9:00 AM CT | 3600 | GastrointestinalPresenter: Eiji Oki, of Perioperative Complications on ctDNA-based MRD Detection and Prognosis: Insights from the GALAXY Study May 31, 9:00 AM CT | 3591 | GastrointestinalPresenter: Emerik Osterlund, M.D., correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study May 31, 9:00 AM CT | 3597 | ColorectalPresenter: Midhun Malla, M.D., dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer May 31, 9:00 AM CT | 4073 | Esophagogastric GastricPresenter: Reetu Mukherji, analysis of over 5000 esophagogastric cancers June 1, 9:00 AM CT | 9574 | Merkel Cell CarcinomaPresenter: Joshua Elbridge ChanComparison of surveillance circulating tumor DNA and merkel polyomavirus antibody titer for detection of merkel cell carcinoma recurrence June 1, 9:00 AM CT | 9571 | MelanomaPresenter: George Ansstas, ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma June 1, 9:00 AM CT | 9523 | MelanomaPresenter: Caroline BurkeyCirculating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study. June 1, 9:00 AM CT | 9584 | MelanomaPresenter: Vincent The-Luc MaSensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients June 1, 9:00 AM CT | 5563 | GynecologicalPresenter: Jung-Yun Lee, M.D., monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) with or without the anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 June 2, 9:00 AM CT | 4565 | GenitourinaryPresenter: Adanma Ayanambakkam, of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC) June 2, 9:00 AM CT | 4602 | GenitourinaryPresenter: Ilana EpsteinCorrelation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT) June 2, 9:00 AM CT | 4560 | GenitourinaryPresenter: Kevin R. Reyes, BSCirculating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with Enfortumab Vedotin +/- Pembrolizumab (EVP) June 2, 9:00 AM CT | TPS620 | BreastPresenter: Michail Ignatiadis, M.D., Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) June 2, 9:00 AM CT | 581 | BreastPresenter: Julia Foldi, M.D., circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes June 2, 9:00 AM CT | 560 | BreastPresenter: Marla Lipsyc-Sharf, of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC) June 2, 9:00 AM CT | 612 | BreastPresenter: Mei Wei, M.D.I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC) June 2, 1:30 PM CT | 3142 | PancancerPresenter: Mridula George, performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors June 2, 1:30 PM CT | 3048 | GastrointestinalPresenter: John Paul Y.C. Shen, of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA About Signatera Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera's leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment. 'The depth and breadth of Natera's research at ASCO is our most significant to date, with multiple impactful datasets in several histologies,' said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. 'The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed.' Highlights include: DARE Clinical Trial: Oral Presentation DARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of 'treatment on molecular recurrence' (TOMR). Patients who were Signatera-positive and imaging-negative were randomized into two arms: the standard-of-care (SOC) arm with endocrine therapy vs. the escalated arm with fulvestrant+palbociclib (CDK 4/6i). This interim analysis of 507 women and 2,208 plasma samples demonstrates the exceptional clinical performance of Signatera, and the early feasibility of both this treatment escalation approach and the TOMR trial strategy, including: Strong test sensitivity and NPV: Among patients who remained persistently Signatera-negative during screening (>400 pts), 99% remained recurrence free with a median follow up of 27.4 months. High randomization rate: Of patients who tested Signatera-positive, 73% were negative on imaging, and 93% were willing to be randomized. 2x higher ctDNA clearance: Patients in Arm A had a 2x higher rate of ctDNA clearance at 3 months vs. Arm B. Signatera Monitoring in Metastatic Breast Cancer: Oral Presentation This real-world analysis of over 600 metastatic breast cancer (mBC) patients across all disease subtypes and a wide range of therapeutic regimens (e.g., chemo, ADCs, CDK4/6) shows the utility of metastatic monitoring with Signatera: Serial ctDNA testing done at an appropriate cadence (6 weeks) can inform treatment response and clinical decisions in metastatic breast cancer. Signatera ctDNA dynamics were the strongest predictor of treatment benefit in a multivariate analysis, based on measuring time to next treatment (TTNT). Nearly 75% of patients with favorable dynamics remained on the same treatment for over 4 months, including those receiving antibody drug conjugates (ADCs) where therapy response can be challenging to evaluate on imaging. Pan-Cancer Performance of Signatera Genome: Poster Presentation Large-scale presentation of Signatera's Genome assay, analyzing more than 3,000 samples from over 300 patients across 5 major cancer types. The study includes analysis of patients with breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma. Signatera Performance in Post-Surgical Stage I-IIIb Melanoma: Poster Presentation This study includes 197 patients and 1,681 plasma samples, tested for a median period of 2 years. This is one of the most comprehensive MRD/monitoring datasets thus far in early melanoma, demonstrating the ability of Signatera to identify patients who may benefit from escalated imaging or earlier treatment initiation. Post-surgical Signatera-positivity was the most significant predictor of recurrence free survival (RFS). In the surveillance setting, Signatera-positivity was predictive of shorter RFS (HR: 24.0, P < 0.001). Full list of oral presentations at ASCO: May 30, 2:45 PM CT | 3008 | Breast Presenter: Silver Alkhafaji Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial June 1, 9:45 AM CT | 4503 | Genitourinary Presenter: Thomas Powles, MBBS, MRCP, M.D. Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA June 1, 11:30 AM CT | 3518 | Gastrointestinal Presenter: Aron Bercz, M.D. Circulating Tumor DNA Provides an Early Response Assessment in Anal Squamous Cell Carcinoma Treated With Definitive Chemoradiation June 1, 4:30 PM CT | 1010 | Breast Presenter: Lajos Pusztai, M.D., DPhil Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer (BC) during adjuvant endocrine therapy (ET) (DARE) June 1, 4:30 PM CT | 1011 | Breast Presenter: Pedram Razavi, M.D., Ph.D. Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC) June 2, 3:00 PM CT | 504 | Breast Presenter: Rita Mukhtar, M.D. Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial Full list of poster presentations at ASCO: May 31, 9:00 AM CT | 11537 | Sarcoma Presenter: Adie Victor, M.D., M.S. Early on-treatment circulating tumor (ct)DNA dynamics in response to therapy in patients with sarcoma May 31, 9:00 AM CT | 11531 | Sarcoma Presenter: Maggie Zhou, M.D. Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma May 31, 9:00 AM CT | TPS3647 | Gastrointestinal Presenter: Clara Montagut, M.D. A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS Trial. May 31, 9:00 AM CT | 4067 | Gastrointestinal - FMI Presenter: Michele Prisciandaro, M.D. Tumor-informed liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: the LIQUID study May 31, 9:00 AM CT | 4130 | Gastrointestinal Presenter: Maen Abdelrahim, M.D. Real-world analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer May 31, 9:00 AM CT | 3600 | Gastrointestinal Presenter: Eiji Oki, Ph.D. Impact of Perioperative Complications on ctDNA-based MRD Detection and Prognosis: Insights from the GALAXY Study May 31, 9:00 AM CT | 3591 | Gastrointestinal Presenter: Emerik Osterlund, M.D., Ph.D. Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study May 31, 9:00 AM CT | 3597 | Colorectal Presenter: Midhun Malla, M.D., M.S. ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer May 31, 9:00 AM CT | 4073 | Esophagogastric Gastric Presenter: Reetu Mukherji, M.D. Exome analysis of over 5000 esophagogastric cancers June 1, 9:00 AM CT | 9574 | Merkel Cell Carcinoma Presenter: Joshua Elbridge Chan Comparison of surveillance circulating tumor DNA and merkel polyomavirus antibody titer for detection of merkel cell carcinoma recurrence June 1, 9:00 AM CT | 9571 | Melanoma Presenter: George Ansstas, M.D. Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma June 1, 9:00 AM CT | 9523 | Melanoma Presenter: Caroline Burkey Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study. June 1, 9:00 AM CT | 9584 | Melanoma Presenter: Vincent The-Luc Ma Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients June 1, 9:00 AM CT | 5563 | Gynecological Presenter: Jung-Yun Lee, M.D., Ph.D. ctDNA monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) with or without the anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 June 2, 9:00 AM CT | 4565 | Genitourinary Presenter: Adanma Ayanambakkam, M.D. Association of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC) June 2, 9:00 AM CT | 4602 | Genitourinary Presenter: Ilana Epstein Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT) June 2, 9:00 AM CT | 4560 | Genitourinary Presenter: Kevin R. Reyes, BS Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with Enfortumab Vedotin +/- Pembrolizumab (EVP) June 2, 9:00 AM CT | TPS620 | Breast Presenter: Michail Ignatiadis, M.D., Ph.D. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) June 2, 9:00 AM CT | 581 | Breast Presenter: Julia Foldi, M.D., Ph.D. Serial circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes June 2, 9:00 AM CT | 560 | Breast Presenter: Marla Lipsyc-Sharf, M.D. Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC) June 2, 9:00 AM CT | 612 | Breast Presenter: Mei Wei, M.D. I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC) June 2, 1:30 PM CT | 3142 | Pancancer Presenter: Mridula George, M.D. Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors June 2, 1:30 PM CT | 3048 | Gastrointestinal Presenter: John Paul Y.C. Shen, M.D. Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA About Signatera Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 250 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and
Yahoo
13-05-2025
- Business
- Yahoo
Natera, Inc. (NTRA): A Bull Case Theory
We came across a bullish thesis on Natera, Inc. (NTRA) on Substack by FJ Research. In this article, we will summarize the bulls' thesis on NTRA. Natera, Inc. (NTRA)'s share was trading at $162.57 as of May 8th. A doctor in a medical laboratory wearing a protective suit and a face mask, running a molecular diagnostic test. Natera is emerging as one of the most pivotal companies in the transformation of global healthcare, and its significance has not gone unnoticed by legendary investor Stanley Druckenmiller—who has made it his largest position. Known for his nearly unmatched track record, including 30%+ annual returns over decades and prescient bets on tech, AI, and energy, Druckenmiller only invests his own capital and swings hard when the upside far outweighs the risk. His conviction in Natera is a signal worth paying close attention to. When someone with his foresight and discipline makes such a concentrated bet, it suggests the company's long-term potential may be vastly underappreciated by the broader market. Natera specializes in non-invasive, DNA-based diagnostic testing with a mission to shift healthcare from reactive treatment to proactive detection. Its key platforms—Signatera™ for monitoring cancer recurrence, Prospera™ for transplant rejection, and Panorama™ for prenatal screening—are category-defining technologies. These aren't incremental improvements; they're transformative solutions targeting massive, underserved markets. Signatera leads in the fast-growing minimal residual disease (MRD) space, helping detect cancer recurrence earlier than traditional methods. Prospera offers real-time organ transplant health monitoring, while Panorama is already widely used in prenatal care. Together, these platforms could reshape how millions are diagnosed and treated. The company is growing rapidly, backed by years of research and clinical validation. Natera's diagnostics are gaining traction in mainstream medical practice, and institutional confidence is high—early backing from Sequoia Capital reinforces its credibility. Beyond technology, Natera's founding story adds emotional weight to its mission. Founder Matthew Rabinowitz launched the company after losing a family member to a preventable genetic condition, fueling his drive to bring early detection into the medical mainstream. That personal origin is reflected in the company's culture and long-term vision. Despite operating in a highly technical and regulated industry, Natera's business is increasingly about inevitability. AI and computational biology are finally disrupting healthcare, and Natera is at the center of this shift. The company's addressable market is vast, especially in oncology, where early detection can dramatically improve outcomes and lower costs. For investors, this represents a rare opportunity: a company with real-world impact, strong growth, deep competitive moats, and the endorsement of one of the greatest investors of our time. Druckenmiller's high-conviction bet highlights what's at stake—and why Natera may be one of the most essential and undervalued healthcare companies of the next decade. Natera, Inc. (NTRA) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 77 hedge fund portfolios held NTRA at the end of the fourth quarter which was 62 in the previous quarter. While we acknowledge the risk and potential of NTRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NTRA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
11-05-2025
- Business
- Yahoo
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Natera, Inc. (NASDAQ:NTRA) just released its latest first-quarter results and things are looking bullish. Revenues of US$502m were better than expected, some 12% ahead of forecasts. The company still lost a statutory US$0.50 per share, although the losses were 19% smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year. Our free stock report includes 2 warning signs investors should be aware of before investing in Natera. Read for free now. Taking into account the latest results, the current consensus from Natera's 20 analysts is for revenues of US$1.97b in 2025. This would reflect a reasonable 7.4% increase on its revenue over the past 12 months. Losses are forecast to balloon 58% to US$2.21 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$1.92b and losses of US$2.13 per share in 2025. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although there was a nice uplift to revenue, the consensus also made a modest increase to its losses per share forecasts. View our latest analysis for Natera The consensus price target stayed unchanged at US$192, seeming to suggest that higher forecast losses are not expected to have a long term impact on the valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Natera analyst has a price target of US$251 per share, while the most pessimistic values it at US$37.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Natera's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Natera's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 10.0% growth on an annualised basis. This is compared to a historical growth rate of 33% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 18% per year. Factoring in the forecast slowdown in growth, it seems obvious that Natera is also expected to grow slower than other industry participants. The most important thing to take away is that the analysts increased their loss per share estimates for next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. The consensus price target held steady at US$192, with the latest estimates not enough to have an impact on their price targets. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Natera analysts - going out to 2027, and you can see them free on our platform here. We don't want to rain on the parade too much, but we did also find 2 warning signs for Natera that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
